In conclusion, we have developed and validated a novel tumor-specific T cell signature (including VAMP5, TIGIT, LCK, CD27, and CACYBP) as a prognostic biomarker for bladder cancer patients treated with immunotherapy using single cell multi-omics data. This evidence concerns the gene TIGIT and urinary bladder cancer.